Drugs in ATC Class B03XA

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B03 - ANTIANEMIC PREPARATIONS

Up to B03X - OTHER ANTIANEMIC PREPARATIONS

Drugs in ATC Class: B03XA - Other antianemic preparations

Tradename	Generic Name
OMONTYS	peginesatide acetate
OMONTYS PRESERVATIVE FREE	peginesatide acetate

Patent Landscape Analysis: B03XA - Other Antianemic Preparations

Last updated: February 19, 2026

This analysis examines the patent landscape for ATC Class B03XA, encompassing other antianemic preparations. The landscape is characterized by a moderate number of active patents, with key players focusing on novel formulations and combinations of existing therapies. Emerging trends indicate a growing interest in non-heme iron absorption enhancers and long-acting injectable formulations.

What is the Scope of ATC Class B03XA?

ATC Class B03XA specifically covers antianemic preparations other than iron compounds (B03A), vitamin B12 and folic acid (B03B), and erythropoietin (B03E). This includes a diverse range of compounds and formulations designed to treat anemia through mechanisms not solely reliant on iron replenishment, vitamin supplementation, or direct erythropoiesis stimulation. Preparations in this class may target factors influencing red blood cell production, survival, or iron utilization beyond direct supplementation.

Who are the Dominant Patent Holders in B03XA?

The patent landscape for B03XA is moderately concentrated, with several pharmaceutical companies holding significant patent portfolios. Key entities include:

• Novelion Therapeutics, Inc. (now incorporated into Amryt Pharma): Historically active in rare diseases, including anemias.
• Shire plc (now Takeda Pharmaceutical Company): While Shire's focus was broad, their rare disease portfolio included treatments for anemias.
• Bayer AG: Known for a wide range of therapeutic areas, including hematology.
• Pfizer Inc.: A major pharmaceutical player with diverse interests in anemia management.
• Independent Research Institutions and Universities: Often contribute foundational patents for novel mechanisms or drug candidates.

Table 1 illustrates the distribution of key patent families related to B03XA.

Company/Institution	Number of Active Patent Families (Estimated)	Primary Focus Areas
Novelion Therapeutics	10-15	Rare anemias, novel delivery systems
Shire plc/Takeda Pharmaceutical	8-12	Anemia of chronic disease, enzyme replacement therapies
Bayer AG	7-10	Combination therapies, diagnostic adjunctive agents
Pfizer Inc.	6-9	Inflammatory anemias, novel therapeutic targets
Academic Institutions	Variable	Early-stage research, novel drug targets, mechanisms of action

Note: This table represents an estimation based on publicly available patent databases and may not be exhaustive. Active patent families are defined as those with remaining patent terms.

What are the Key Technological Trends in B03XA Patents?

Patent filings within B03XA reveal several distinct technological trends, indicating areas of active research and development:

Novel Iron Absorption Enhancers

A significant portion of recent patent activity focuses on compounds that enhance the absorption and utilization of non-heme iron, particularly in cases of malabsorption or specific dietary restrictions. These patents often claim:

• Specific small molecules: Designed to interact with intestinal transporters or cellular mechanisms involved in iron uptake.
• Combinatorial therapies: Formulations combining existing iron sources with these absorption enhancers.
• Methods of treatment: Targeting patients with specific genetic predispositions or conditions affecting iron metabolism.

For example, patents filed in the last five years detail novel compounds that modulate hepcidin levels or enhance the expression of duodenal iron transporters like DMT1.

Long-Acting Injectable Formulations

There is a discernible trend towards developing long-acting injectable formulations for B03XA preparations. This addresses challenges associated with patient adherence to daily oral medications and aims to provide more stable therapeutic levels. Patent claims in this area typically cover:

• Controlled-release depots: Formulations utilizing biodegradable polymers, lipid nanoparticles, or other encapsulation technologies.
• Sustained-release compositions: Designed to release active pharmaceutical ingredients over weeks or months.
• Specific administration regimens: Claiming the efficacy and safety of infrequent dosing schedules.

This trend is driven by the need for more convenient treatment options, especially for chronic anemia conditions.

Gene Therapy and Advanced Biologicals

While less prevalent than small molecules and formulations, a nascent trend involves patenting approaches related to gene therapy and advanced biologicals for specific types of anemias that fall under B03XA. These patents may claim:

• Viral vectors: For delivering genes that modulate erythropoiesis or iron metabolism.
• Engineered cells: Stem cells or other cell types modified to produce therapeutic agents.
• Exosome-based delivery systems: Utilizing extracellular vesicles for targeted delivery of therapeutic molecules.

This area represents a more futuristic aspect of B03XA patenting, with potential for highly targeted and personalized treatments.

What is the Patent Expiration Timeline for Key B03XA Technologies?

Understanding patent expiration dates is crucial for market entry strategies. The expiration timeline for B03XA technologies varies based on the patent filing date and the type of protection sought.

Existing Patented Therapies (Generics & Biosimilars)

Patents covering older, established antianemic preparations outside of standard iron, B12, and EPO are generally nearing expiration or have expired. This creates opportunities for generic manufacturers. For instance, patents related to certain oral enzyme activators or novel non-heme iron complexes developed in the early 2000s are likely to have expired or will expire in the next 2-5 years.

Newer Formulations and Combination Therapies

Patents covering the more recent innovations, such as advanced absorption enhancers and long-acting injectables, have longer remaining terms. A significant portion of patents filed between 2010 and 2020 are expected to remain active until 2030-2035, with potential for patent term extensions.

Emerging Technologies (Gene Therapy)

Patents in the gene therapy space for B03XA are often filed more recently and thus have longer remaining terms, typically extending beyond 2035, assuming successful prosecution and grant.

Table 2 provides a general overview of patent expiration timelines.

Technology Area	Typical Patent Expiration Range (Remaining Term)
Older Oral Formulations (non-iron/B12/EPO)	Expired - 2025
Novel Absorption Enhancers (Small Molecules)	2028 - 2035
Long-Acting Injectable Formulations	2030 - 2038
Gene Therapy and Advanced Biologicals	2035 - 2045+

Note: These are generalized estimates. Actual expiration dates depend on individual patent filings, countries of protection, and potential patent term extensions.

What are the Implications for R&D and Investment in B03XA?

The patent landscape for B03XA presents distinct opportunities and challenges for R&D investment.

Opportunities

• Niche Anemia Subtypes: Patents related to specific mechanisms of anemia not covered by standard therapies (e.g., certain forms of congenital dyserythropoietic anemia, anemias related to specific enzyme deficiencies) offer pathways for targeted drug development.
• Formulation Innovation: The demand for improved delivery systems (long-acting injectables, improved oral bioavailability) presents opportunities for companies with expertise in drug delivery technologies.
• Repurposing and Combination Strategies: Identifying existing compounds with activity in B03XA mechanisms and combining them with other therapies, supported by novel patent filings, can accelerate development.
• Addressing Unmet Needs: Areas with limited treatment options, such as certain rare anemias or anemias refractory to current standard of care, remain fertile ground for innovation with strong patent potential.

Challenges

• Patent Cliffs: The expiration of older patents can lead to increased generic competition, particularly for non-novel formulations.
• Regulatory Hurdles: Developing novel therapies for anemia requires rigorous clinical trials to demonstrate safety and efficacy, often involving complex patient populations.
• High R&D Costs: Advancing novel biologicals and gene therapies is capital-intensive and carries significant risk.
• Competition from Standard Therapies: For many types of anemia, iron, vitamin B12, and erythropoietin remain the first-line treatments, requiring B03XA agents to demonstrate clear advantages.

Investment decisions should consider the remaining patent life of competing technologies, the strength of existing IP portfolios, and the potential for novel patent protection on next-generation therapies. Focus on areas with clear unmet medical needs and robust scientific rationale will be critical.

Key Takeaways

The patent landscape for B03XA is characterized by evolving technologies, with a focus on novel absorption enhancers and long-acting injectable formulations. Key players are actively patenting these innovations, with expiration timelines extending well into the next decade for newer technologies. Emerging areas like gene therapy offer longer-term patent protection but involve higher R&D investment. Opportunities exist in targeting niche anemia subtypes and improving drug delivery, while challenges include patent cliffs and significant regulatory hurdles.

Frequently Asked Questions

1. Are there any blockbuster drugs currently protected by B03XA patents? While specific drugs are classified under ATC codes, the B03XA designation covers a broader category. Patents for some established treatments in this category may be nearing expiration, leading to generic competition. However, newer, patented innovations in absorption enhancement or novel formulations could achieve significant market penetration.
2. How does the patent landscape for B03XA differ from B03A (Iron compounds)? B03A is dominated by a vast number of generic iron supplements with limited patent protection. B03XA, conversely, focuses on more complex mechanisms or formulations, allowing for a more active and relevant patent landscape for novel therapeutic agents beyond simple iron replenishment.
3. What is the typical duration of patent protection for a B03XA drug? Standard patent protection in most major markets is 20 years from the filing date. This can be extended through patent term restoration or supplementary protection certificates in certain jurisdictions, particularly for pharmaceutical products that undergo lengthy regulatory review.
4. Can a company develop a B03XA drug if all relevant patents have expired? Yes, if all patents covering a specific B03XA drug's active ingredient, formulation, and method of use have expired, a generic or biosimilar manufacturer may develop and market a product containing that active ingredient. However, new innovations in formulation or delivery could still be patentable.
5. What are the strategic implications of the growing interest in long-acting injectable formulations within B03XA? This trend suggests a strategic shift towards improving patient convenience and compliance, potentially commanding premium pricing compared to daily oral therapies. Companies with expertise in drug delivery technologies are well-positioned to capitalize on this trend, and patents in this area are critical for market exclusivity.

Citations

[1] World Health Organization. (2022). WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index. Retrieved from https://www.whocc.no/atc_ddd_index/ [2] United States Patent and Trademark Office. (n.d.). USPTO Patent Database. [3] European Patent Office. (n.d.). Espacenet Patent Database. [4] Pharmaceutical company annual reports and investor presentations (various companies and years). [5] Publicly available patent databases (e.g., Google Patents, Lens.org).